Copyright Reports & Markets. All rights reserved.

Global and China Antibody Drug Conjugates (ADCs) Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Antibody Drug Conjugates (ADCs) Market Size Growth Rate by Type: 2020 VS 2026
    • 1.2.2 Seattle Genetics Technology
    • 1.2.3 ImmunoGen Technology
    • 1.2.4 Immunomedics Technology
  • 1.3 Market by Application
    • 1.3.1 Global Antibody Drug Conjugates (ADCs) Market Share by Application: 2020 VS 2026
    • 1.3.2 Hospital
    • 1.3.3 Clinics
    • 1.3.4 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Antibody Drug Conjugates (ADCs) Market Perspective (2015-2026)
  • 2.2 Global Antibody Drug Conjugates (ADCs) Growth Trends by Regions
    • 2.2.1 Antibody Drug Conjugates (ADCs) Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Antibody Drug Conjugates (ADCs) Historic Market Share by Regions (2015-2020)
    • 2.2.3 Antibody Drug Conjugates (ADCs) Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Antibody Drug Conjugates (ADCs) Players by Market Size
    • 3.1.1 Global Top Antibody Drug Conjugates (ADCs) Players by Revenue (2015-2020)
    • 3.1.2 Global Antibody Drug Conjugates (ADCs) Revenue Market Share by Players (2015-2020)
  • 3.2 Global Antibody Drug Conjugates (ADCs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Antibody Drug Conjugates (ADCs) Revenue
  • 3.4 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio
    • 3.4.1 Global Antibody Drug Conjugates (ADCs) Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugates (ADCs) Revenue in 2019
  • 3.5 Key Players Antibody Drug Conjugates (ADCs) Area Served
  • 3.6 Key Players Antibody Drug Conjugates (ADCs) Product Solution and Service
  • 3.7 Date of Enter into Antibody Drug Conjugates (ADCs) Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Antibody Drug Conjugates (ADCs) Breakdown Data by Type (2015-2026)

  • 4.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Type (2015-2020)
  • 4.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Type (2021-2026)

5 Antibody Drug Conjugates (ADCs) Breakdown Data by Application (2015-2026)

  • 5.1 Global Antibody Drug Conjugates (ADCs) Historic Market Size by Application (2015-2020)
  • 5.2 Global Antibody Drug Conjugates (ADCs) Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Antibody Drug Conjugates (ADCs) Market Size (2015-2026)
  • 6.2 North America Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
  • 6.3 North America Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)
  • 6.4 North America Antibody Drug Conjugates (ADCs) Market Size by Country (2015-2020)
    • 6.4.1 United States
    • 6.4.2 Canada

7 Europe

  • 7.1 Europe Antibody Drug Conjugates (ADCs) Market Size (2015-2026)
  • 7.2 Europe Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
  • 7.3 Europe Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)
  • 7.4 Europe Antibody Drug Conjugates (ADCs) Market Size by Country (2015-2020)
    • 7.4.1 Germany
    • 7.4.2 France
    • 7.4.3 U.K.
    • 7.4.4 Italy
    • 7.4.5 Russia
    • 7.4.6 Nordic
    • 7.4.7 Rest of Europe

8 China

  • 8.1 China Antibody Drug Conjugates (ADCs) Market Size (2015-2026)
  • 8.2 China Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
  • 8.3 China Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)
  • 8.4 China Antibody Drug Conjugates (ADCs) Market Size by Region (2015-2020)
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 South Korea
    • 8.4.4 Southeast Asia
    • 8.4.5 India
    • 8.4.6 Australia
    • 8.4.7 Rest of Asia-Pacific

9 Japan

  • 9.1 Japan Antibody Drug Conjugates (ADCs) Market Size (2015-2026)
  • 9.2 Japan Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
  • 9.3 Japan Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)
  • 9.4 Japan Antibody Drug Conjugates (ADCs) Market Size by Country (2015-2020)
    • 9.4.1 Mexico
    • 9.4.2 Brazil

10 Southeast Asia

  • 10.1 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size (2015-2026)
  • 10.2 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Type (2015-2020)
  • 10.3 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Application (2015-2020)
  • 10.4 Southeast Asia Antibody Drug Conjugates (ADCs) Market Size by Country (2015-2020)
    • 10.4.1 Turkey
    • 10.4.2 Saudi Arabia
    • 10.4.3 UAE
    • 10.4.4 Rest of Middle East & Africa

11 Key Players Profiles

  • 11.1 Roche
    • 11.1.1 Roche Company Details
    • 11.1.2 Roche Business Overview
    • 11.1.3 Roche Antibody Drug Conjugates (ADCs) Introduction
    • 11.1.4 Roche Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020))
    • 11.1.5 Roche Recent Development
  • 11.2 Pfizer
    • 11.2.1 Pfizer Company Details
    • 11.2.2 Pfizer Business Overview
    • 11.2.3 Pfizer Antibody Drug Conjugates (ADCs) Introduction
    • 11.2.4 Pfizer Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.2.5 Pfizer Recent Development
  • 11.3 Novartis
    • 11.3.1 Novartis Company Details
    • 11.3.2 Novartis Business Overview
    • 11.3.3 Novartis Antibody Drug Conjugates (ADCs) Introduction
    • 11.3.4 Novartis Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.3.5 Novartis Recent Development
  • 11.4 Genmab
    • 11.4.1 Genmab Company Details
    • 11.4.2 Genmab Business Overview
    • 11.4.3 Genmab Antibody Drug Conjugates (ADCs) Introduction
    • 11.4.4 Genmab Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.4.5 Genmab Recent Development
  • 11.5 Bayer
    • 11.5.1 Bayer Company Details
    • 11.5.2 Bayer Business Overview
    • 11.5.3 Bayer Antibody Drug Conjugates (ADCs) Introduction
    • 11.5.4 Bayer Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.5.5 Bayer Recent Development
  • 11.6 Seattle Genetics
    • 11.6.1 Seattle Genetics Company Details
    • 11.6.2 Seattle Genetics Business Overview
    • 11.6.3 Seattle Genetics Antibody Drug Conjugates (ADCs) Introduction
    • 11.6.4 Seattle Genetics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.6.5 Seattle Genetics Recent Development
  • 11.7 Takeda Pharmaceuticals
    • 11.7.1 Takeda Pharmaceuticals Company Details
    • 11.7.2 Takeda Pharmaceuticals Business Overview
    • 11.7.3 Takeda Pharmaceuticals Antibody Drug Conjugates (ADCs) Introduction
    • 11.7.4 Takeda Pharmaceuticals Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.7.5 Takeda Pharmaceuticals Recent Development
  • 11.8 AbbVie
    • 11.8.1 AbbVie Company Details
    • 11.8.2 AbbVie Business Overview
    • 11.8.3 AbbVie Antibody Drug Conjugates (ADCs) Introduction
    • 11.8.4 AbbVie Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.8.5 AbbVie Recent Development
  • 11.9 AbGenomics
    • 11.9.1 AbGenomics Company Details
    • 11.9.2 AbGenomics Business Overview
    • 11.9.3 AbGenomics Antibody Drug Conjugates (ADCs) Introduction
    • 11.9.4 AbGenomics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.9.5 AbGenomics Recent Development
  • 11.10 ADC Therapeutics
    • 11.10.1 ADC Therapeutics Company Details
    • 11.10.2 ADC Therapeutics Business Overview
    • 11.10.3 ADC Therapeutics Antibody Drug Conjugates (ADCs) Introduction
    • 11.10.4 ADC Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 11.10.5 ADC Therapeutics Recent Development
  • 11.11 Astellas Pharma
    • 10.11.1 Astellas Pharma Company Details
    • 10.11.2 Astellas Pharma Business Overview
    • 10.11.3 Astellas Pharma Antibody Drug Conjugates (ADCs) Introduction
    • 10.11.4 Astellas Pharma Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 10.11.5 Astellas Pharma Recent Development
  • 11.12 Kairos Therapeutics
    • 10.12.1 Kairos Therapeutics Company Details
    • 10.12.2 Kairos Therapeutics Business Overview
    • 10.12.3 Kairos Therapeutics Antibody Drug Conjugates (ADCs) Introduction
    • 10.12.4 Kairos Therapeutics Revenue in Antibody Drug Conjugates (ADCs) Business (2015-2020)
    • 10.12.5 Kairos Therapeutics Recent Development

12 Analyst's Viewpoints/Conclusions

    13 Appendix

    • 13.1 Research Methodology
      • 13.1.1 Methodology/Research Approach
      • 13.1.2 Data Source
    • 13.2 Disclaimer

    Global Antibody Drug Conjugates (ADCs) Scope and Market Size
    Antibody Drug Conjugates (ADCs) market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Antibody Drug Conjugates (ADCs) market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    Market segment by Type, the product can be split into
    Seattle Genetics Technology
    ImmunoGen Technology
    Immunomedics Technology

    Market segment by Application, split into
    Hospital
    Clinics
    Others

    Based on regional and country-level analysis, the Antibody Drug Conjugates (ADCs) market has been segmented as follows:
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Nordic
    Rest of Europe
    Asia-Pacific
    China
    Japan
    South Korea
    Southeast Asia
    India
    Australia
    Rest of Asia-Pacific
    Latin America
    Mexico
    Brazil
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE
    Rest of Middle East & Africa

    In the competitive analysis section of the report, leading as well as prominent players of the global Antibody Drug Conjugates (ADCs) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
    The key players covered in this study
    Roche
    Pfizer
    Novartis
    Genmab
    Bayer
    Seattle Genetics
    Takeda Pharmaceuticals
    AbbVie
    AbGenomics
    ADC Therapeutics
    Astellas Pharma
    Kairos Therapeutics

    Buy now